

**Evolving IP Marketplace -- Comment, Project No. PO93900**

The Need for Distinct Claims  
Submitted by ZymoGenetics, Inc.  
Suzanne M. Shema

ZymoGenetics, Inc. is a biopharmaceutical company that owes its existence and success to confidence in the U.S. patent system. Its scientists have made numerous patented

inventions, and second, the need for the development of Section 112 standards as applied

new genes and proteins. Those rules were added to the U.S. Code of Federal Regulations and applicants are required to follow them.

D. Greater Clarity of Specifications and Claims Facilitate Biotech Searches and Analyses. Section 112 standards, as well as the standards developed voluntarily

patent system. They help applicants use common terminology and draft more comprehensible specifications and claims. They help applicants and patent examiners create criteria for searching the prior art and analyzing the difference

performing the claimed function. In September 2008, the USPTO clarified its policy on indefiniteness rejections and has begun applying that policy in decisions by the Board of Patent Appeals and Interferences. FTC should encourage the courts' and USPTO's development of legal standards for "definiteness", particularly in the context of High Tech inventions. The development of more rigorous definiteness standards will permit courts to "weed out the patent thicket"

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

just as the written description requirement was created and is applied (almost

~~just as the written description requirement was created and is applied (almost~~